64Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Serbia
Neuroscience Intelligence
Serbia neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #40 of 50 · Data maturity A · Research score 29.4 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
15Recruiting trials
12Publications
13Institutions
Executive interpretation
Serbia ranks #40 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Sumitomo Pharma America, Inc.50 recruiting
Hoffmann-La Roche41 recruiting
Boehringer Ingelheim30 recruiting
Eisai Limited30 recruiting
Genzyme, a Sanofi Company30 recruiting
H. Lundbeck A/S21 recruiting
ACADIA Pharmaceuticals Inc.20 recruiting
Forest Laboratories20 recruiting
Celgene20 recruiting
AbbVie20 recruiting
Disease activity
Epilepsy9trials
Multiple Sclerosis9trials
Alzheimers8trials
Neuromuscular7trials
Parkinsons6trials
Schizophrenia6trials
Depression4trials
Autism3trials
Stroke2trials
Bipolar Disorder2trials
Research institutions
Vinča Institute of Nuclear SciencesOpenAlexlinked institution
University of DefenceOpenAlexlinked institution
Univerzitetski Klinički Centar SrbijeOpenAlexlinked institution
Zemun HospitalOpenAlexlinked institution
Singidunum UniversityOpenAlexlinked institution
Military Medical AcademyOpenAlexlinked institution
Centar za Promociju NaukeOpenAlexlinked institution
University of NisOpenAlexlinked institution
University of KragujevacOpenAlexlinked institution
Clinical Centre of KragujevacOpenAlexlinked institution
Clinical evidence trail
NCT07067463A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06744920A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia GravisRECRUITING
NCT06701903Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety DisorderRECRUITING
NCT06463587Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RECRUITING
NCT06298552A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisACTIVE_NOT_RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05549258Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum DisorderRECRUITING
Research evidence trail
PUBMEDICD-11 PTSD and CPTSD in Serbia: clinical validation of the International Trauma Questionnaire.2026-12-01
PUBMEDSex-related phenotypic differences in myotonic dystrophy types 1 and 2: a nationwide registry study from Serbia.2026-10-06
PUBMEDImpact of Severity of Autism on Auditory Behaviour and Receptive Vocabulary in Autism Spectrum Disorder.2026-10-01
PUBMEDFFAR2 activation induces IL-22-dependent intestinal immune responses to suppress CNS autoimmunity.2026-10-01
PUBMEDPrevalence and Correlates of Significant Posttraumatic Stress Disorder Symptoms in Children in Ukraine.2026-10-01
PUBMEDVertebral Artery Hypoplasia and Posterior Circulation Vulnerability: A Systematic Review of Epidemiological, Hemodynamic, and Clinical Evidence.2026-09-01
PUBMEDThe Influence of Serum Iron Levels on Depression, Anxiety, Fatigue, Neuropathic Pain and MR Disease Activity in Patients with Multiple Sclerosis.2026-07-27
PUBMEDMigraine Prevalence and QALY Loss in Serbia: A Population-Level Stratified Modeling Study.2026-01-01
OPENALEXBeneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 20212021-07-15
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.